Founder leaves Curavec for health reasons

Alongside Biontech, Curevac was actually the great German hope in the fight against the Corona pandemic. But its drug disappointed in an efficacy test. Now, founder Ingmar Hoerr and another member of the supervisory board are apparently leaving the company.

The bad news at Curavec does not seem to stop: After the company announced last week that at this point the Corona vaccine it developed is only 47 percent effective, founder Ingmar Hoerr is leaving Curavec for good, according to a report. He had founded the company in 2000, and had already left last year after suffering a brain hemorrhage. Now a spokesman for Curavec announced that Hoerr will not run again for the supervisory board for health reasons.

It's not the only personnel matter: since 2019 Timothy M. Wright sat on the supervisory board, now he is leaving Curavec again to pursue his own professional tasks, according to a report by Manager Magazine. At the time, he had been brought into the company primarily to support the mRNA technology on which Curavec's Corona vaccine is now based.

Last week, the company released interim results of a study on the efficacy of its developed Corona vaccine, which came in at just 47 percent. As a result, the company's stock price temporarily plummeted by half. After Biontech, Curevac is the second German company to develop a vaccine using mRNA technology.